Literature DB >> 1910448

What is the basis for HLA-DQ associations with autoimmune disease?

D M Altmann1, D Sansom, S G Marsh.   

Abstract

The finding that diseases such as type I diabetes, coeliac disease and multiple sclerosis are HLA-DQ associated is not easily explained by a simple hypothesis of DQ-restricted, autoreactive T cells, considering the generally marginal role of DQ in restricting responses. Consequently, there have been various attempts to find a differential role for DQ, from presentation of special antigens to preferential stimulation of suppressor cells. Here, Daniel Altmann and colleagues critically assess these proposals and put forward the alternative hypothesis that the effect of DQ on disease susceptibility may result from a special role in shaping the T-cell receptor repertoire.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1910448     DOI: 10.1016/0167-5699(91)90124-C

Source DB:  PubMed          Journal:  Immunol Today        ISSN: 0167-5699


  25 in total

1.  Characterization of recombination in the HLA class II region.

Authors:  M Cullen; J Noble; H Erlich; K Thorpe; S Beck; W Klitz; J Trowsdale; M Carrington
Journal:  Am J Hum Genet       Date:  1997-02       Impact factor: 11.025

2.  Similar antigenic surfaces, rather than sequence homology, dictate T-cell epitope molecular mimicry.

Authors:  S Quaratino; C J Thorpe; P J Travers; M Londei
Journal:  Proc Natl Acad Sci U S A       Date:  1995-10-24       Impact factor: 11.205

3.  Human CD4-major histocompatibility complex class II (DQw6) transgenic mice in an endogenous CD4/CD8-deficient background: reconstitution of phenotype and human-restricted function.

Authors:  R S Yeung; J M Penninger; T M Kündig; Y Law; K Yamamoto; N Kamikawaji; L Burkly; T Sasazuki; R Flavell; P S Ohashi; T W Mak
Journal:  J Exp Med       Date:  1994-11-01       Impact factor: 14.307

4.  HLA class-I and -II antigens in chronic idiopathic autoimmune thrombocytopenia.

Authors:  A Gaiger; A Neumeister; H Heinzl; I Pabinger; S Panzer
Journal:  Ann Hematol       Date:  1994-06       Impact factor: 3.673

5.  Increased epithelial expression of HLA-DQ and HLA-DP molecules in salivary glands from patients with Sjögren's syndrome compared with obstructive sialadenitis.

Authors:  P S Thrane; T S Halstensen; H R Haanaes; P Brandtzaeg
Journal:  Clin Exp Immunol       Date:  1993-05       Impact factor: 4.330

6.  Immunohistochemical changes in the jejunum in first degree relatives of patients with coeliac disease and the coeliac disease marker DQ genes. HLA class II antigen expression, interleukin-2 receptor positive cells and dividing crypt cells.

Authors:  K Holm; E Savilahti; S Koskimies; V Lipsanen; M Mäki
Journal:  Gut       Date:  1994-01       Impact factor: 23.059

7.  Correlation of molecular human leukocyte antigen typing and outcome in high-risk melanoma patients receiving adjuvant interferon.

Authors:  Helen Gogas; John M Kirkwood; Christine S Falk; Urania Dafni; Vernon K Sondak; Dimosthenis Tsoutsos; Alexandros Stratigos; Christos Markopoulos; Dimitrios Pectasides; Maria Spyropoulou-Vlachou
Journal:  Cancer       Date:  2010-09-15       Impact factor: 6.860

8.  Insulin autoantibodies and high titre islet cell antibodies are preferentially associated with the HLA DQA1*0301-DQB1*0302 haplotype at clinical type 1 (insulin-dependent) diabetes mellitus before age 10 years, but not at onset between age 10 and 40 years. The Belgian Diabetes Registry.

Authors:  C L Vandewalle; T Decraene; F C Schuit; I H De Leeuw; D G Pipeleers; F K Gorus
Journal:  Diabetologia       Date:  1993-11       Impact factor: 10.122

9.  Lymphocyte subset abnormalities, autoantibodies and their relationship with HLA DR types in children with type 1 (insulin-dependent) diabetes and their first degree relatives.

Authors:  M Peakman; T Warnock; A Vats; G L McNab; J Underhill; P T Donaldson; D Vergani
Journal:  Diabetologia       Date:  1994-02       Impact factor: 10.122

10.  Association between HLA DQB1 * 03 and cervical intra-epithelial neoplasia.

Authors:  K Odunsi; G Terry; L Ho; J Bell; J Cuzick; T S Ganesan
Journal:  Mol Med       Date:  1995-01       Impact factor: 6.354

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.